english.prescrire.org > Prescrire International > N°147 - March 2014

n°147

March 2014

Issue Contents
Editorial

Free  The gap between benefits and harms

p.60
Viewing the benefits through the prism of the harms

New Products


Dapagliflozin (New Drug)

p.61-64
A hypoglycaemic drug causing disproportionate harm, especially to kidneys

Free  Tenofovir and chronic hepatitis B (New Indication)

p.65
Adolescents: an antiviral drug with inadequately documented adverse effects on the kidneys and bone

Bortezomib: with longer follow-up (A Second Look)

p.66-67
Myeloma: after failure of thalidomide

INN common stem: -gliflozin

p.67

Adverse Effects


Frequency of the adverse effects of lithium

p.68-69
Patient education is essential

Venous sclerotherapy with lauromacrogol 400: thrombosis, ischaemia

p.70-71
Rare but potentially serious

Colchicine: cytotoxic drug overdose

p.71
Monitor patients with renal failure

Nimesulide: good riddance to a dangerous NSAID in France

p.72
More hepatotoxic than other NSAIDs

Valproic acid in utero: autism

p.72
A population-based study in Denmark

Risperidone, paliperidone, quetiapine: floppy iris syndrome

p.72
Alpha-adrenergic blocking effects are implicated

Reviews


Preventing rickets with vitamin D

p.73-78
Supplementation for some children

Clinical signs of vitamin D-deficiency rickets

p.75

Outlook


Free  2013 Prescrire Awards

p.79-83

Free  2013 Prescrire Drug Awards

p.80

Free  2013 Prescrire Information Awards

p.81

Free  2013 Prescrire Packaging Awards

p.82-83

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe